Stockscreener 앱 받기
46.38
3.87%
1.73
시간 외 거래:
46.38
Mirum Pharmaceuticals Inc 주식(MIRM)의 최신 뉴스
Why Is Mirum Pharmaceuticals (MIRM) Down 1.3% Since Last Earnings Report? - Yahoo Finance
Insider Sell: Saira Ramasastry Sells 8,203 Shares of Mirum Pharm - GuruFocus
Mirum Pharmaceuticals director sells shares totaling $377,843 By Investing.com - Investing.com India
Mirum Pharmaceuticals director sells shares totaling $377,843 - Investing.com
(MIRM) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Mirum pharmaceuticals raises 2025 revenue guidance to $435M-$450M driven by robust growth - MSN
Mirum Pharmaceuticals Holds 2025 Annual Stockholders Meeting - TipRanks
Alagille Syndrome Treatment Market Detailed in New Research ReportMirum Pharmaceuticals, Albireo Pharma - openPR.com
Two Sigma Investments LP Has $5.23 Million Stock Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Man Group plc Invests $289,000 in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - Defense World
Mirum Pharmaceuticals’ SWOT analysis: rare disease stock shows growth potential By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals’ SWOT analysis: rare disease stock shows growth potential - Investing.com Nigeria
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Cuts Stock Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - Defense World
When the Price of (MIRM) Talks, People Listen - news.stocktradersdaily.com
Mirum Pharmaceuticals (MIRM) – Research Analysts’ Weekly Ratings Changes - Defense World
What is HC Wainwright’s Estimate for MIRM Q2 Earnings? - Defense World
Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer - citybiz
Comerica Bank Reduces Stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - Defense World
Mirum Pharmaceuticals (NASDAQ:MIRM) Given “Buy” Rating at HC Wainwright - Defense World
Mirum Pharmaceuticals Names Doug Sheehy New Chief Legal Officer - Bloomberg Law News
Mirum Pharmaceuticals (MIRM) Receives Buy Rating from HC Wainwri - GuruFocus
Mirum Pharmaceuticals (MIRM) Appoints New Chief Legal Officer | - GuruFocus
Mirum Pharmaceuticals (MIRM) Receives Buy Rating from HC Wainwright & Co. | MIRM Stock News - GuruFocus
Mirum Pharmaceuticals (MIRM) Receives Buy Rating with Promising Growth Potential | MIRM Stock News - GuruFocus
Analysts Set Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Price Target at $60.64 - Defense World
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q1 2025 Earnings Call Transcript - MSN
Northern Trust Corp Acquires 32,059 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - Defense World
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Sold by The Manufacturers Life Insurance Company - Defense World
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences - Business Wire
Mirum Pharmaceuticals (MIRM) Maintains Strong Buy Rating with Ra - GuruFocus
Mirum Pharmaceuticals (MIRM) Gets Price Target Boost to $77 | MI - GuruFocus
Trend Tracker for (MIRM) - news.stocktradersdaily.com
FY2025 EPS Estimates for MIRM Raised by Cantor Fitzgerald - Defense World
Leerink Partnrs Brokers Increase Earnings Estimates for MIRM - Defense World
JMP Securities Increases Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $76.00 - Defense World
Mirum Pharmaceuticals (MIRM) Price Target Raised Following Stron - GuruFocus
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Beyond The Numbers: 4 Analysts Discuss Mirum Pharmaceuticals Stock - Benzinga
Mirum Pharmaceuticals (MIRM) Maintains Market Outperform Rating with Higher Price Target | MIRM Stock News - GuruFocus
Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised - MSN
Volixibat Data from Mirum’s VANTAGE PBC Study Showcased at EASL - Business Wire
Mirum Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
JMP raises Mirum Pharmaceuticals stock target to $76 By Investing.com - Investing.com Canada
Mirum Pharmaceuticals (MIRM) Price Target Raised Following Strong Revenue Outlook | MIRM Stock News - GuruFocus
Evercore ISI lifts Mirum stock target to $76, maintains outperform By Investing.com - Investing.com Canada
Evercore ISI lifts Mirum stock target to $76, maintains outperform - Investing.com
Mirum Pharmaceuticals Reports Strong Q1 2025 Results - TipRanks
Earnings call transcript: Mirum Pharmaceuticals beats Q1 2025 revenue forecasts - Investing.com
Mirum Pharmaceuticals beats Q1 estimates, raises 2025 guidance; shares rise - Investing.com Nigeria
1.21%
1.51%
자본화:
|
볼륨(24시간):